Log in Free sign up

Vallon Pharmaceuticals (VLON) News and press releases

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

12 Health Care Stocks Moving In Tuesday's After-Market Session

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Tuesday, 540 companies set new 52-week lows.

73 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 198 companies reached new 52-week lows.

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

Biotech, Earnings, News, IPOs, Trading Ideas, General

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

30 Stocks Moving in Monday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.

110 Biggest Movers From Friday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.

12 Health Care Stocks Moving In Friday's Intraday Session

Intraday Update, Markets, Movers

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 153 companies set new 52-week lows.

Vallon Pharmaceuticals Announces $3.9M Registered Direct Offering; 3.7M Shares At $1.0632/Share

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter

Vallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS Stimulant

Biotech, News, Penny Stocks, Health Care, General

Vallon Pharmaceuticals Reports Additional Pharmacokinetic And Pharmacodynamic Data From SEAL Study Of ADAIR

Biotech, General

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Vallon Pharma Reports Issued Japanese Patent Covering Composition Of Matter, Methods Of Manufacturing For ADAIR Abuse-Deterrent Formulation Of Immediate-Release Dextroamphetamine

Biotech, News, FDA, Legal, General

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter

Vallon Pharmaceuticals Q1 Net Loss $2.6M

Vallon Pharmaceuticals (NASDAQ:VLON) will report on Q1 2022.

71 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Tuesday's Intraday Session

Intraday Update, Markets, Movers

60 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Monday's Intraday Session

Intraday Update, Markets, Movers

Press releases

From Benzinga Pro

Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs

Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs

Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR

PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs

Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs

Thinking about buying stock in Vallon Pharmaceuticals, Snap, Sundial Growers, Bitnile, or Cyngn?

Opinion, Press Releases

NEW YORK, April 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLON, SNAP, SNDL, NILE, and CYN.

Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD

– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All pharmacodynamic

Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors

Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies

Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19

- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVID-19